Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.
MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
It is indicated in patients who have received at least one prior therapy, or in first-line treatment for patients unsuitable for chemo-immunotherapy
Findings from the CheckMate 142 study in patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer
Updated results from the monarchE study point to abemaciclib benefit regardless of Ki-67 status
Findings from a phase I study of selective ROR1 targeting
Evidence for efficacy is based on the results from the KEYNOTE-826 study
New indication concerns the treatment of PD-L1 positive locally recurrent unresectable or metastatic TNBC
Statistical calibration allows for comparison of tumour mutational burden values across various panel assays
Third vaccine dose could be immunologically beneficial for patients on active chemotherapy
Integrated molecular-morphologic meningiomas classification by the German Consortium on Aggressive Meningiomas
A portion of the OncoKB is recognised as a source of valid scientific evidence for Level 2 and Level 3 biomarkers
Evidence for efficacy is based on the results from the ZUMA-3 study
Findings from the ITACA study in patients with completely resected, stage II-IIIA non-small cell lung cancer
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.
